Between 1992 and 1993, pharmaceutical sales growth in Canada slowed to 7.7%, reaching a value of C$11.8 billion ($8.60 billion) as price controls and difficulties in market access for products took their toll, according to the just-published 1994 annual review of the Pharmaceutical Manufacturers Association of Canada.
R&D spending increased 390% from C$103 million in 1987 to C$504 million in 1993. Counting R&D spending of all PMAC members, the ratio of sales to research was 12% in 1993, the review notes. Basic or discovery research has grown almost 300% since 1998, it adds. The pharmaceutical industry accounted for one-third of all Canadian health research spending in 1993, up from 18% in 1998.
122 New Chemical Entities were approved for sale between 1988 and 1993. Half were for products in cardiovascular, anti-infective/antiviral and central nervous system therapeutic categories. The review notes, however, that it takes almost twice as long for a new drug submission to get approved in Canada as it does in Sweden or the UK.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze